At a Glance
- Companies: Eli Lilly and Ascidian Therapeutics
- Deal value: Up to $1.9 billion
- Focus area: RNA exon editing
- Goal: Develop therapies for genetic diseases
- Next steps: Advance partnered programmes and research
What happened?
Eli Lilly and Ascidian Therapeutics have entered into an RNA exon editing partnership valued at up to $1.9 billion. The agreement gives Lilly access to Ascidian’s platform for editing RNA at the exon level, a newer approach to treating disease.
Why does it matter?
RNA exon editing could offer a way to correct disease-causing genetic changes without permanently altering DNA. That makes it an attractive strategy for genetic disorders where a more precise, potentially reversible intervention may be valuable.
Who’s behind it?
Eli Lilly is a major global pharmaceutical company with a growing interest in advanced genetic medicine. Ascidian Therapeutics is a biotech focused on RNA editing technologies that aim to broaden the reach of nucleic-acid-based therapies.
How was it achieved?
The partnership is built around Ascidian’s exon editing platform, which is designed to modify RNA transcripts rather than DNA. That could allow the companies to address conditions caused by mutations in specific exons while potentially avoiding some of the risks associated with genome editing.
What’s next?
The companies are expected to identify and progress programmes under the collaboration, with milestone payments tied to research and development success. The deal also positions Lilly to expand further into next-generation genetic medicine.